nodes	percent_of_prediction	percent_of_DWPC	metapath
Captopril—MMP2—sarcoma	0.655	1	CbGaD
Captopril—REN—renal vein—sarcoma	0.0138	0.0978	CbGeAlD
Captopril—REN—posterior vena cava—sarcoma	0.0101	0.0714	CbGeAlD
Captopril—ABCB1—Dactinomycin—sarcoma	0.00887	0.262	CbGbCtD
Captopril—ABCB1—Mitoxantrone—sarcoma	0.00794	0.234	CbGbCtD
Captopril—F2—posterior vena cava—sarcoma	0.00704	0.0498	CbGeAlD
Captopril—REN—forelimb zeugopod—sarcoma	0.00655	0.0463	CbGeAlD
Captopril—ABCB1—Vincristine—sarcoma	0.00546	0.161	CbGbCtD
Captopril—ABCB1—Etoposide—sarcoma	0.00501	0.148	CbGbCtD
Captopril—REN—pulmonary artery—sarcoma	0.0049	0.0346	CbGeAlD
Captopril—MMP2—dermis—sarcoma	0.00462	0.0326	CbGeAlD
Captopril—F2—knee—sarcoma	0.00422	0.0298	CbGeAlD
Captopril—MMP9—dermis—sarcoma	0.00402	0.0284	CbGeAlD
Captopril—ABCB1—Doxorubicin—sarcoma	0.00341	0.101	CbGbCtD
Captopril—MMP9—periosteum—sarcoma	0.00333	0.0235	CbGeAlD
Captopril—CYP2D6—Doxorubicin—sarcoma	0.00322	0.0949	CbGbCtD
Captopril—REN—arm—sarcoma	0.00283	0.02	CbGeAlD
Captopril—ACE—forelimb zeugopod—sarcoma	0.00279	0.0197	CbGeAlD
Captopril—MMP2—hindlimb—sarcoma	0.00272	0.0192	CbGeAlD
Captopril—MMP2—cartilage tissue—sarcoma	0.00268	0.0189	CbGeAlD
Captopril—REN—appendage—sarcoma	0.00254	0.018	CbGeAlD
Captopril—MMP9—hindlimb—sarcoma	0.00237	0.0167	CbGeAlD
Captopril—MMP2—appendage—sarcoma	0.00234	0.0165	CbGeAlD
Captopril—MMP9—cartilage tissue—sarcoma	0.00233	0.0165	CbGeAlD
Captopril—F2—leg—sarcoma	0.00231	0.0163	CbGeAlD
Captopril—F2—forelimb—sarcoma	0.0023	0.0162	CbGeAlD
Captopril—ACE—pulmonary artery—sarcoma	0.00209	0.0147	CbGeAlD
Captopril—F2—hindlimb—sarcoma	0.00207	0.0146	CbGeAlD
Captopril—MMP9—appendage—sarcoma	0.00203	0.0144	CbGeAlD
Captopril—F2—appendage—sarcoma	0.00177	0.0125	CbGeAlD
Captopril—LTA4H—mammary gland—sarcoma	0.0016	0.0113	CbGeAlD
Captopril—MMP2—endothelium—sarcoma	0.00141	0.00996	CbGeAlD
Captopril—ACE—forelimb—sarcoma	0.0014	0.00991	CbGeAlD
Captopril—ACE—umbilical vein—sarcoma	0.00138	0.00974	CbGeAlD
Captopril—ACE—hindlimb—sarcoma	0.00126	0.00892	CbGeAlD
Captopril—MMP9—endothelium—sarcoma	0.00123	0.00866	CbGeAlD
Captopril—ACE—arm—sarcoma	0.00121	0.00852	CbGeAlD
Captopril—LTA4H—myometrium—sarcoma	0.00114	0.00803	CbGeAlD
Captopril—MMP2—mammary gland—sarcoma	0.00114	0.00803	CbGeAlD
Captopril—LTA4H—embryo—sarcoma	0.00109	0.00772	CbGeAlD
Captopril—ACE—appendage—sarcoma	0.00108	0.00765	CbGeAlD
Captopril—F2—endothelium—sarcoma	0.00107	0.00756	CbGeAlD
Captopril—LTA4H—seminal vesicle—sarcoma	0.00103	0.00725	CbGeAlD
Captopril—LTA4H—hematopoietic system—sarcoma	0.000976	0.0069	CbGeAlD
Captopril—LTA4H—connective tissue—sarcoma	0.000939	0.00664	CbGeAlD
Captopril—REN—myometrium—sarcoma	0.000877	0.0062	CbGeAlD
Captopril—F2—mammary gland—sarcoma	0.000862	0.00609	CbGeAlD
Captopril—LTA4H—smooth muscle tissue—sarcoma	0.000859	0.00607	CbGeAlD
Captopril—MMP2—myometrium—sarcoma	0.000806	0.0057	CbGeAlD
Captopril—MMP2—embryo—sarcoma	0.000775	0.00548	CbGeAlD
Captopril—REN—hematopoietic system—sarcoma	0.000753	0.00532	CbGeAlD
Captopril—LTA4H—cardiac atrium—sarcoma	0.000741	0.00524	CbGeAlD
Captopril—LTA4H—uterus—sarcoma	0.000737	0.00521	CbGeAlD
Captopril—MMP2—seminal vesicle—sarcoma	0.000728	0.00515	CbGeAlD
Captopril—REN—connective tissue—sarcoma	0.000725	0.00512	CbGeAlD
Captopril—MMP2—hematopoietic system—sarcoma	0.000692	0.00489	CbGeAlD
Captopril—LTA4H—lymphoid tissue—sarcoma	0.000687	0.00485	CbGeAlD
Captopril—MMP9—embryo—sarcoma	0.000674	0.00477	CbGeAlD
Captopril—MMP2—connective tissue—sarcoma	0.000667	0.00471	CbGeAlD
Captopril—REN—smooth muscle tissue—sarcoma	0.000663	0.00469	CbGeAlD
Captopril—ACE—endothelium—sarcoma	0.000653	0.00462	CbGeAlD
Captopril—LTA4H—tendon—sarcoma	0.000646	0.00456	CbGeAlD
Captopril—LTA4H—bone marrow—sarcoma	0.000625	0.00442	CbGeAlD
Captopril—MMP2—smooth muscle tissue—sarcoma	0.00061	0.00431	CbGeAlD
Captopril—MMP9—hematopoietic system—sarcoma	0.000602	0.00425	CbGeAlD
Captopril—MMP2—skin of body—sarcoma	0.000602	0.00425	CbGeAlD
Captopril—MMP9—connective tissue—sarcoma	0.00058	0.0041	CbGeAlD
Captopril—REN—cardiac atrium—sarcoma	0.000572	0.00404	CbGeAlD
Captopril—ALB—mammary gland—sarcoma	0.00055	0.00389	CbGeAlD
Captopril—LTA4H—testis—sarcoma	0.000535	0.00378	CbGeAlD
Captopril—MMP9—smooth muscle tissue—sarcoma	0.00053	0.00375	CbGeAlD
Captopril—MMP2—cardiac atrium—sarcoma	0.000526	0.00371	CbGeAlD
Captopril—F2—hematopoietic system—sarcoma	0.000525	0.00371	CbGeAlD
Captopril—MMP9—skin of body—sarcoma	0.000523	0.0037	CbGeAlD
Captopril—MMP2—uterus—sarcoma	0.000523	0.0037	CbGeAlD
Captopril—F2—connective tissue—sarcoma	0.000506	0.00357	CbGeAlD
Captopril—LTA4H—liver—sarcoma	0.000505	0.00357	CbGeAlD
Captopril—MMP2—lymphoid tissue—sarcoma	0.000487	0.00344	CbGeAlD
Captopril—MMP2—tendon—sarcoma	0.000458	0.00324	CbGeAlD
Captopril—MMP9—uterus—sarcoma	0.000455	0.00321	CbGeAlD
Captopril—MMP9—lymphoid tissue—sarcoma	0.000424	0.003	CbGeAlD
Captopril—MMP9—tendon—sarcoma	0.000398	0.00282	CbGeAlD
Captopril—REN—liver—sarcoma	0.00039	0.00276	CbGeAlD
Captopril—LTA4H—lymph node—sarcoma	0.000388	0.00274	CbGeAlD
Captopril—MMP9—bone marrow—sarcoma	0.000386	0.00273	CbGeAlD
Captopril—MMP2—testis—sarcoma	0.000379	0.00268	CbGeAlD
Captopril—F2—lymphoid tissue—sarcoma	0.00037	0.00261	CbGeAlD
Captopril—ACE—embryo—sarcoma	0.000359	0.00254	CbGeAlD
Captopril—MMP2—liver—sarcoma	0.000359	0.00253	CbGeAlD
Captopril—ACE—seminal vesicle—sarcoma	0.000338	0.00239	CbGeAlD
Captopril—F2—bone marrow—sarcoma	0.000337	0.00238	CbGeAlD
Captopril—MMP9—testis—sarcoma	0.00033	0.00233	CbGeAlD
Captopril—ACE—hematopoietic system—sarcoma	0.000321	0.00227	CbGeAlD
Captopril—MMP9—liver—sarcoma	0.000312	0.0022	CbGeAlD
Captopril—ACE—connective tissue—sarcoma	0.000309	0.00218	CbGeAlD
Captopril—ACE—smooth muscle tissue—sarcoma	0.000283	0.002	CbGeAlD
Captopril—MMP2—lymph node—sarcoma	0.000275	0.00194	CbGeAlD
Captopril—F2—liver—sarcoma	0.000272	0.00192	CbGeAlD
Captopril—ACE—cardiac atrium—sarcoma	0.000244	0.00172	CbGeAlD
Captopril—MMP9—lymph node—sarcoma	0.000239	0.00169	CbGeAlD
Captopril—SLC15A1—liver—sarcoma	0.000232	0.00164	CbGeAlD
Captopril—ACE—lymphoid tissue—sarcoma	0.000226	0.0016	CbGeAlD
Captopril—ACE—bone marrow—sarcoma	0.000206	0.00145	CbGeAlD
Captopril—Anaphylactic shock—Mitoxantrone—sarcoma	0.000191	0.00239	CcSEcCtD
Captopril—Photosensitivity—Doxorubicin—sarcoma	0.000191	0.00239	CcSEcCtD
Captopril—Decreased appetite—Dactinomycin—sarcoma	0.000191	0.00239	CcSEcCtD
Captopril—Fatigue—Thiotepa—sarcoma	0.000191	0.00239	CcSEcCtD
Captopril—Dysgeusia—Etoposide—sarcoma	0.00019	0.00239	CcSEcCtD
Captopril—Dermatitis bullous—Epirubicin—sarcoma	0.000189	0.00237	CcSEcCtD
Captopril—Fatigue—Dactinomycin—sarcoma	0.000189	0.00237	CcSEcCtD
Captopril—Constipation—Thiotepa—sarcoma	0.000189	0.00237	CcSEcCtD
Captopril—Shock—Mitoxantrone—sarcoma	0.000188	0.00235	CcSEcCtD
Captopril—Anaphylactoid reaction—Epirubicin—sarcoma	0.000187	0.00234	CcSEcCtD
Captopril—Thrombocytopenia—Mitoxantrone—sarcoma	0.000187	0.00234	CcSEcCtD
Captopril—Anorexia—Vincristine—sarcoma	0.000187	0.00234	CcSEcCtD
Captopril—Tachycardia—Mitoxantrone—sarcoma	0.000186	0.00233	CcSEcCtD
Captopril—Cerebrovascular accident—Epirubicin—sarcoma	0.000185	0.00232	CcSEcCtD
Captopril—ALB—testis—sarcoma	0.000184	0.0013	CbGeAlD
Captopril—Hypotension—Vincristine—sarcoma	0.000183	0.00229	CcSEcCtD
Captopril—MMP9—AP-1 transcription factor network—JUN—sarcoma	0.000183	0.00204	CbGpPWpGaD
Captopril—Feeling abnormal—Thiotepa—sarcoma	0.000182	0.00228	CcSEcCtD
Captopril—Anorexia—Mitoxantrone—sarcoma	0.000182	0.00228	CcSEcCtD
Captopril—Hyponatraemia—Epirubicin—sarcoma	0.000182	0.00228	CcSEcCtD
Captopril—MMP9—AP-1 transcription factor network—CTNNB1—sarcoma	0.000181	0.00202	CbGpPWpGaD
Captopril—Renal failure acute—Doxorubicin—sarcoma	0.000181	0.00227	CcSEcCtD
Captopril—Feeling abnormal—Dactinomycin—sarcoma	0.000181	0.00226	CcSEcCtD
Captopril—Gastrointestinal pain—Thiotepa—sarcoma	0.000181	0.00226	CcSEcCtD
Captopril—Ill-defined disorder—Etoposide—sarcoma	0.00018	0.00226	CcSEcCtD
Captopril—Anaemia—Etoposide—sarcoma	0.00018	0.00225	CcSEcCtD
Captopril—LTA4H—Metabolism—ENO2—sarcoma	0.00018	0.002	CbGpPWpGaD
Captopril—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—sarcoma	0.000179	0.002	CbGpPWpGaD
Captopril—CYP2D6—Melatonin metabolism and effects—FOXO1—sarcoma	0.000179	0.002	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—EZR—sarcoma	0.000179	0.002	CbGpPWpGaD
Captopril—Gastrointestinal pain—Dactinomycin—sarcoma	0.000179	0.00225	CcSEcCtD
Captopril—Musculoskeletal discomfort—Vincristine—sarcoma	0.000179	0.00224	CcSEcCtD
Captopril—LTA4H—Metabolism—HBA1—sarcoma	0.000179	0.00199	CbGpPWpGaD
Captopril—Hypotension—Mitoxantrone—sarcoma	0.000178	0.00223	CcSEcCtD
Captopril—Dermatitis exfoliative—Doxorubicin—sarcoma	0.000178	0.00222	CcSEcCtD
Captopril—Insomnia—Vincristine—sarcoma	0.000177	0.00222	CcSEcCtD
Captopril—MMP9—Plasma membrane estrogen receptor signaling—HRAS—sarcoma	0.000177	0.00197	CbGpPWpGaD
Captopril—MMP9—LPA receptor mediated events—SRC—sarcoma	0.000176	0.00196	CbGpPWpGaD
Captopril—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000176	0.00196	CbGpPWpGaD
Captopril—Paraesthesia—Vincristine—sarcoma	0.000176	0.00221	CcSEcCtD
Captopril—ACE—testis—sarcoma	0.000176	0.00124	CbGeAlD
Captopril—Malaise—Etoposide—sarcoma	0.000175	0.0022	CcSEcCtD
Captopril—Dermatitis bullous—Doxorubicin—sarcoma	0.000175	0.0022	CcSEcCtD
Captopril—Body temperature increased—Thiotepa—sarcoma	0.000175	0.00219	CcSEcCtD
Captopril—Abdominal pain—Thiotepa—sarcoma	0.000175	0.00219	CcSEcCtD
Captopril—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.000174	0.00218	CcSEcCtD
Captopril—ALB—liver—sarcoma	0.000174	0.00123	CbGeAlD
Captopril—Body temperature increased—Dactinomycin—sarcoma	0.000173	0.00217	CcSEcCtD
Captopril—Abdominal pain—Dactinomycin—sarcoma	0.000173	0.00217	CcSEcCtD
Captopril—ALB—Platelet degranulation—VEGFC—sarcoma	0.000173	0.00193	CbGpPWpGaD
Captopril—Anaphylactoid reaction—Doxorubicin—sarcoma	0.000173	0.00217	CcSEcCtD
Captopril—Cardiac arrest—Epirubicin—sarcoma	0.000172	0.00216	CcSEcCtD
Captopril—MMP9—AGE/RAGE pathway—SRC—sarcoma	0.000172	0.00192	CbGpPWpGaD
Captopril—MMP9—Endochondral Ossification—VEGFA—sarcoma	0.000172	0.00191	CbGpPWpGaD
Captopril—Paraesthesia—Mitoxantrone—sarcoma	0.000171	0.00215	CcSEcCtD
Captopril—Loss of consciousness—Etoposide—sarcoma	0.000171	0.00214	CcSEcCtD
Captopril—Cerebrovascular accident—Doxorubicin—sarcoma	0.000171	0.00214	CcSEcCtD
Captopril—Decreased appetite—Vincristine—sarcoma	0.00017	0.00213	CcSEcCtD
Captopril—Ataxia—Epirubicin—sarcoma	0.00017	0.00213	CcSEcCtD
Captopril—Dyspnoea—Mitoxantrone—sarcoma	0.00017	0.00213	CcSEcCtD
Captopril—Cough—Etoposide—sarcoma	0.00017	0.00213	CcSEcCtD
Captopril—Somnolence—Mitoxantrone—sarcoma	0.00017	0.00213	CcSEcCtD
Captopril—Fatigue—Vincristine—sarcoma	0.000169	0.00212	CcSEcCtD
Captopril—Hyponatraemia—Doxorubicin—sarcoma	0.000168	0.00211	CcSEcCtD
Captopril—Dyspepsia—Mitoxantrone—sarcoma	0.000168	0.00211	CcSEcCtD
Captopril—Constipation—Vincristine—sarcoma	0.000168	0.0021	CcSEcCtD
Captopril—ACE—liver—sarcoma	0.000166	0.00117	CbGeAlD
Captopril—Decreased appetite—Mitoxantrone—sarcoma	0.000166	0.00208	CcSEcCtD
Captopril—Chest pain—Etoposide—sarcoma	0.000166	0.00208	CcSEcCtD
Captopril—Orthostatic hypotension—Epirubicin—sarcoma	0.000165	0.00207	CcSEcCtD
Captopril—ALB—Response to elevated platelet cytosolic Ca2+—VEGFC—sarcoma	0.000165	0.00184	CbGpPWpGaD
Captopril—F2—Peptide ligand-binding receptors—CXCR4—sarcoma	0.000165	0.00184	CbGpPWpGaD
Captopril—MMP9—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—sarcoma	0.000165	0.00183	CbGpPWpGaD
Captopril—Fatigue—Mitoxantrone—sarcoma	0.000165	0.00206	CcSEcCtD
Captopril—MMP9—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—sarcoma	0.000164	0.00183	CbGpPWpGaD
Captopril—Discomfort—Etoposide—sarcoma	0.000164	0.00205	CcSEcCtD
Captopril—Constipation—Mitoxantrone—sarcoma	0.000163	0.00205	CcSEcCtD
Captopril—MMP9—Regulation of nuclear beta catenin signaling and target gene transcription—CTNNB1—sarcoma	0.000163	0.00182	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—PTPRC—sarcoma	0.000161	0.0018	CbGpPWpGaD
Captopril—Gastrointestinal pain—Vincristine—sarcoma	0.00016	0.00201	CcSEcCtD
Captopril—MMP2—Direct p53 effectors—JUN—sarcoma	0.00016	0.00178	CbGpPWpGaD
Captopril—Confusional state—Etoposide—sarcoma	0.00016	0.00201	CcSEcCtD
Captopril—Muscular weakness—Epirubicin—sarcoma	0.00016	0.002	CcSEcCtD
Captopril—Cardiac arrest—Doxorubicin—sarcoma	0.000159	0.002	CcSEcCtD
Captopril—Anaphylactic shock—Etoposide—sarcoma	0.000159	0.00199	CcSEcCtD
Captopril—Asthenia—Thiotepa—sarcoma	0.000159	0.00199	CcSEcCtD
Captopril—MMP2—Developmental Biology—PLCG1—sarcoma	0.000158	0.00176	CbGpPWpGaD
Captopril—Ataxia—Doxorubicin—sarcoma	0.000158	0.00197	CcSEcCtD
Captopril—Asthenia—Dactinomycin—sarcoma	0.000157	0.00197	CcSEcCtD
Captopril—Feeling abnormal—Mitoxantrone—sarcoma	0.000157	0.00197	CcSEcCtD
Captopril—CYP2D6—hematopoietic system—sarcoma	0.000157	0.00111	CbGeAlD
Captopril—Pruritus—Thiotepa—sarcoma	0.000156	0.00196	CcSEcCtD
Captopril—Gastrointestinal pain—Mitoxantrone—sarcoma	0.000156	0.00196	CcSEcCtD
Captopril—Thrombocytopenia—Etoposide—sarcoma	0.000155	0.00195	CcSEcCtD
Captopril—Tachycardia—Etoposide—sarcoma	0.000155	0.00194	CcSEcCtD
Captopril—Eosinophilia—Epirubicin—sarcoma	0.000155	0.00194	CcSEcCtD
Captopril—Body temperature increased—Vincristine—sarcoma	0.000155	0.00194	CcSEcCtD
Captopril—Abdominal pain—Vincristine—sarcoma	0.000155	0.00194	CcSEcCtD
Captopril—MMP9—LPA receptor mediated events—EGFR—sarcoma	0.000154	0.00172	CbGpPWpGaD
Captopril—Pancreatitis—Epirubicin—sarcoma	0.000153	0.00192	CcSEcCtD
Captopril—Orthostatic hypotension—Doxorubicin—sarcoma	0.000153	0.00192	CcSEcCtD
Captopril—MMP2—Extracellular matrix organization—KDR—sarcoma	0.000153	0.0017	CbGpPWpGaD
Captopril—MMP9—Signaling by SCF-KIT—KIT—sarcoma	0.000153	0.0017	CbGpPWpGaD
Captopril—LTA4H—Metabolism—PLCG1—sarcoma	0.000152	0.0017	CbGpPWpGaD
Captopril—Angina pectoris—Epirubicin—sarcoma	0.000152	0.00191	CcSEcCtD
Captopril—F2—Folate Metabolism—IL2—sarcoma	0.000152	0.0017	CbGpPWpGaD
Captopril—Anorexia—Etoposide—sarcoma	0.000151	0.0019	CcSEcCtD
Captopril—Diarrhoea—Thiotepa—sarcoma	0.000151	0.00189	CcSEcCtD
Captopril—Body temperature increased—Mitoxantrone—sarcoma	0.000151	0.00189	CcSEcCtD
Captopril—Abdominal pain—Mitoxantrone—sarcoma	0.000151	0.00189	CcSEcCtD
Captopril—MMP9—AGE/RAGE pathway—EGFR—sarcoma	0.000151	0.00168	CbGpPWpGaD
Captopril—Diarrhoea—Dactinomycin—sarcoma	0.00015	0.00188	CcSEcCtD
Captopril—Pancytopenia—Epirubicin—sarcoma	0.000149	0.00186	CcSEcCtD
Captopril—Hypotension—Etoposide—sarcoma	0.000148	0.00186	CcSEcCtD
Captopril—MMP9—Axon guidance—PTPRC—sarcoma	0.000148	0.00165	CbGpPWpGaD
Captopril—Muscular weakness—Doxorubicin—sarcoma	0.000148	0.00185	CcSEcCtD
Captopril—F2—Regulation of Actin Cytoskeleton—PDGFRB—sarcoma	0.000148	0.00164	CbGpPWpGaD
Captopril—ALB—Selenium Micronutrient Network—HBA1—sarcoma	0.000148	0.00164	CbGpPWpGaD
Captopril—MMP9—AP-1 transcription factor network—MYC—sarcoma	0.000147	0.00164	CbGpPWpGaD
Captopril—Neutropenia—Epirubicin—sarcoma	0.000146	0.00183	CcSEcCtD
Captopril—MMP9—Developmental Biology—MYOD1—sarcoma	0.000146	0.00163	CbGpPWpGaD
Captopril—Dizziness—Thiotepa—sarcoma	0.000146	0.00183	CcSEcCtD
Captopril—F2—Regulation of Actin Cytoskeleton—PDGFRA—sarcoma	0.000145	0.00162	CbGpPWpGaD
Captopril—MMP9—Signaling by SCF-KIT—CREB1—sarcoma	0.000145	0.00162	CbGpPWpGaD
Captopril—MMP9—Axon guidance—PLCG1—sarcoma	0.000145	0.00162	CbGpPWpGaD
Captopril—Pollakiuria—Epirubicin—sarcoma	0.000145	0.00181	CcSEcCtD
Captopril—Eosinophilia—Doxorubicin—sarcoma	0.000143	0.0018	CcSEcCtD
Captopril—Photosensitivity reaction—Epirubicin—sarcoma	0.000143	0.00179	CcSEcCtD
Captopril—Paraesthesia—Etoposide—sarcoma	0.000143	0.00179	CcSEcCtD
Captopril—Pancreatitis—Doxorubicin—sarcoma	0.000142	0.00178	CcSEcCtD
Captopril—MMP9—CXCR4-mediated signaling events—SRC—sarcoma	0.000142	0.00158	CbGpPWpGaD
Captopril—Weight decreased—Epirubicin—sarcoma	0.000142	0.00177	CcSEcCtD
Captopril—Dyspnoea—Etoposide—sarcoma	0.000142	0.00177	CcSEcCtD
Captopril—Somnolence—Etoposide—sarcoma	0.000141	0.00177	CcSEcCtD
Captopril—Angina pectoris—Doxorubicin—sarcoma	0.000141	0.00177	CcSEcCtD
Captopril—Asthenia—Vincristine—sarcoma	0.000141	0.00176	CcSEcCtD
Captopril—Vomiting—Thiotepa—sarcoma	0.000141	0.00176	CcSEcCtD
Captopril—Vomiting—Dactinomycin—sarcoma	0.000139	0.00175	CcSEcCtD
Captopril—Rash—Thiotepa—sarcoma	0.000139	0.00175	CcSEcCtD
Captopril—Dermatitis—Thiotepa—sarcoma	0.000139	0.00174	CcSEcCtD
Captopril—MMP2—EPH-Ephrin signaling—HRAS—sarcoma	0.000139	0.00155	CbGpPWpGaD
Captopril—Headache—Thiotepa—sarcoma	0.000138	0.00173	CcSEcCtD
Captopril—Stevens-Johnson syndrome—Epirubicin—sarcoma	0.000138	0.00173	CcSEcCtD
Captopril—Rash—Dactinomycin—sarcoma	0.000138	0.00173	CcSEcCtD
Captopril—Decreased appetite—Etoposide—sarcoma	0.000138	0.00173	CcSEcCtD
Captopril—Pancytopenia—Doxorubicin—sarcoma	0.000138	0.00172	CcSEcCtD
Captopril—Renal failure—Epirubicin—sarcoma	0.000137	0.00172	CcSEcCtD
Captopril—Asthenia—Mitoxantrone—sarcoma	0.000137	0.00172	CcSEcCtD
Captopril—Fatigue—Etoposide—sarcoma	0.000137	0.00172	CcSEcCtD
Captopril—Jaundice—Epirubicin—sarcoma	0.000136	0.0017	CcSEcCtD
Captopril—Stomatitis—Epirubicin—sarcoma	0.000136	0.0017	CcSEcCtD
Captopril—F2—Hemostasis—TEK—sarcoma	0.000136	0.00151	CbGpPWpGaD
Captopril—Constipation—Etoposide—sarcoma	0.000136	0.0017	CcSEcCtD
Captopril—Neutropenia—Doxorubicin—sarcoma	0.000135	0.0017	CcSEcCtD
Captopril—Diarrhoea—Vincristine—sarcoma	0.000134	0.00168	CcSEcCtD
Captopril—Pollakiuria—Doxorubicin—sarcoma	0.000134	0.00168	CcSEcCtD
Captopril—ABCB1—HIF-1-alpha transcription factor network—CXCR4—sarcoma	0.000134	0.00149	CbGpPWpGaD
Captopril—MMP9—Validated targets of C-MYC transcriptional activation—MYC—sarcoma	0.000133	0.00149	CbGpPWpGaD
Captopril—ALB—lymph node—sarcoma	0.000133	0.000941	CbGeAlD
Captopril—Photosensitivity reaction—Doxorubicin—sarcoma	0.000132	0.00166	CcSEcCtD
Captopril—MMP9—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—sarcoma	0.000132	0.00147	CbGpPWpGaD
Captopril—ABCB1—myometrium—sarcoma	0.000132	0.00093	CbGeAlD
Captopril—Nausea—Thiotepa—sarcoma	0.000131	0.00164	CcSEcCtD
Captopril—Weight decreased—Doxorubicin—sarcoma	0.000131	0.00164	CcSEcCtD
Captopril—Feeling abnormal—Etoposide—sarcoma	0.000131	0.00164	CcSEcCtD
Captopril—Diarrhoea—Mitoxantrone—sarcoma	0.000131	0.00164	CcSEcCtD
Captopril—Nausea—Dactinomycin—sarcoma	0.00013	0.00163	CcSEcCtD
Captopril—Agranulocytosis—Epirubicin—sarcoma	0.00013	0.00163	CcSEcCtD
Captopril—Gastrointestinal pain—Etoposide—sarcoma	0.00013	0.00163	CcSEcCtD
Captopril—MMP2—Axon guidance—KDR—sarcoma	0.00013	0.00145	CbGpPWpGaD
Captopril—Dizziness—Vincristine—sarcoma	0.00013	0.00162	CcSEcCtD
Captopril—MMP9—EPH-Ephrin signaling—SRC—sarcoma	0.00013	0.00144	CbGpPWpGaD
Captopril—Stevens-Johnson syndrome—Doxorubicin—sarcoma	0.000128	0.0016	CcSEcCtD
Captopril—ACE—lymph node—sarcoma	0.000127	0.000901	CbGeAlD
Captopril—Renal failure—Doxorubicin—sarcoma	0.000127	0.00159	CcSEcCtD
Captopril—ABCB1—embryo—sarcoma	0.000127	0.000894	CbGeAlD
Captopril—MMP9—EPH-Ephrin signaling—VEGFA—sarcoma	0.000126	0.00141	CbGpPWpGaD
Captopril—MMP2—Direct p53 effectors—EGFR—sarcoma	0.000126	0.0014	CbGpPWpGaD
Captopril—Stomatitis—Doxorubicin—sarcoma	0.000126	0.00158	CcSEcCtD
Captopril—Jaundice—Doxorubicin—sarcoma	0.000126	0.00158	CcSEcCtD
Captopril—Rhinitis—Epirubicin—sarcoma	0.000126	0.00157	CcSEcCtD
Captopril—Body temperature increased—Etoposide—sarcoma	0.000125	0.00157	CcSEcCtD
Captopril—Abdominal pain—Etoposide—sarcoma	0.000125	0.00157	CcSEcCtD
Captopril—Hepatitis—Epirubicin—sarcoma	0.000125	0.00157	CcSEcCtD
Captopril—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRB—sarcoma	0.000125	0.00139	CbGpPWpGaD
Captopril—Vomiting—Vincristine—sarcoma	0.000125	0.00156	CcSEcCtD
Captopril—Pharyngitis—Epirubicin—sarcoma	0.000124	0.00156	CcSEcCtD
Captopril—F2—Hemostasis—ANGPT2—sarcoma	0.000124	0.00138	CbGpPWpGaD
Captopril—MMP9—LPA receptor mediated events—HRAS—sarcoma	0.000124	0.00138	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—IL2—sarcoma	0.000124	0.00138	CbGpPWpGaD
Captopril—Rash—Vincristine—sarcoma	0.000124	0.00155	CcSEcCtD
Captopril—Dermatitis—Vincristine—sarcoma	0.000123	0.00155	CcSEcCtD
Captopril—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—sarcoma	0.000123	0.00137	CbGpPWpGaD
Captopril—Headache—Vincristine—sarcoma	0.000123	0.00154	CcSEcCtD
Captopril—Vomiting—Mitoxantrone—sarcoma	0.000121	0.00152	CcSEcCtD
Captopril—MMP9—AP-1 transcription factor network—TP53—sarcoma	0.000121	0.00134	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—CCND1—sarcoma	0.000121	0.00134	CbGpPWpGaD
Captopril—Agranulocytosis—Doxorubicin—sarcoma	0.00012	0.00151	CcSEcCtD
Captopril—Rash—Mitoxantrone—sarcoma	0.00012	0.00151	CcSEcCtD
Captopril—Dermatitis—Mitoxantrone—sarcoma	0.00012	0.00151	CcSEcCtD
Captopril—MMP9—Signaling by SCF-KIT—MDM2—sarcoma	0.00012	0.00134	CbGpPWpGaD
Captopril—Headache—Mitoxantrone—sarcoma	0.00012	0.0015	CcSEcCtD
Captopril—ABCB1—seminal vesicle—sarcoma	0.000119	0.00084	CbGeAlD
Captopril—Erythema multiforme—Epirubicin—sarcoma	0.000118	0.00148	CcSEcCtD
Captopril—REN—Metabolism of proteins—MMP2—sarcoma	0.000117	0.00131	CbGpPWpGaD
Captopril—Nausea—Vincristine—sarcoma	0.000116	0.00146	CcSEcCtD
Captopril—Flushing—Epirubicin—sarcoma	0.000116	0.00146	CcSEcCtD
Captopril—Rhinitis—Doxorubicin—sarcoma	0.000116	0.00146	CcSEcCtD
Captopril—Hepatitis—Doxorubicin—sarcoma	0.000116	0.00145	CcSEcCtD
Captopril—Pharyngitis—Doxorubicin—sarcoma	0.000115	0.00144	CcSEcCtD
Captopril—Asthenia—Etoposide—sarcoma	0.000114	0.00143	CcSEcCtD
Captopril—MMP2—Axon guidance—CREB1—sarcoma	0.000114	0.00127	CbGpPWpGaD
Captopril—Nausea—Mitoxantrone—sarcoma	0.000113	0.00142	CcSEcCtD
Captopril—ABCB1—hematopoietic system—sarcoma	0.000113	0.000798	CbGeAlD
Captopril—ALB—FOXA2 and FOXA3 transcription factor networks—CREB1—sarcoma	0.000113	0.00126	CbGpPWpGaD
Captopril—Pruritus—Etoposide—sarcoma	0.000112	0.00141	CcSEcCtD
Captopril—MMP2—Developmental Biology—FOXO1—sarcoma	0.000112	0.00125	CbGpPWpGaD
Captopril—Alopecia—Epirubicin—sarcoma	0.000111	0.00139	CcSEcCtD
Captopril—F2—Class A/1 (Rhodopsin-like receptors)—CXCR4—sarcoma	0.000111	0.00123	CbGpPWpGaD
Captopril—Erythema multiforme—Doxorubicin—sarcoma	0.00011	0.00137	CcSEcCtD
Captopril—MMP9—Validated targets of C-MYC transcriptional activation—TP53—sarcoma	0.00011	0.00122	CbGpPWpGaD
Captopril—Diarrhoea—Etoposide—sarcoma	0.000109	0.00136	CcSEcCtD
Captopril—Flushing—Doxorubicin—sarcoma	0.000108	0.00135	CcSEcCtD
Captopril—Tension—Epirubicin—sarcoma	0.000107	0.00134	CcSEcCtD
Captopril—Dysgeusia—Epirubicin—sarcoma	0.000107	0.00134	CcSEcCtD
Captopril—Nervousness—Epirubicin—sarcoma	0.000106	0.00133	CcSEcCtD
Captopril—MMP9—Developmental Biology—PTPRC—sarcoma	0.000106	0.00118	CbGpPWpGaD
Captopril—MMP2—Direct p53 effectors—TP53—sarcoma	0.000106	0.00118	CbGpPWpGaD
Captopril—Dizziness—Etoposide—sarcoma	0.000105	0.00132	CcSEcCtD
Captopril—MMP9—Developmental Biology—PLCG1—sarcoma	0.000103	0.00115	CbGpPWpGaD
Captopril—Vision blurred—Epirubicin—sarcoma	0.000103	0.00129	CcSEcCtD
Captopril—Alopecia—Doxorubicin—sarcoma	0.000102	0.00128	CcSEcCtD
Captopril—Ill-defined disorder—Epirubicin—sarcoma	0.000101	0.00127	CcSEcCtD
Captopril—Vomiting—Etoposide—sarcoma	0.000101	0.00126	CcSEcCtD
Captopril—Anaemia—Epirubicin—sarcoma	0.000101	0.00126	CcSEcCtD
Captopril—MMP9—Extracellular matrix organization—KDR—sarcoma	0.0001	0.00112	CbGpPWpGaD
Captopril—Rash—Etoposide—sarcoma	0.0001	0.00125	CcSEcCtD
Captopril—Dermatitis—Etoposide—sarcoma	0.0001	0.00125	CcSEcCtD
Captopril—F2—Hemostasis—VEGFC—sarcoma	9.97e-05	0.00111	CbGpPWpGaD
Captopril—Headache—Etoposide—sarcoma	9.94e-05	0.00125	CcSEcCtD
Captopril—Tension—Doxorubicin—sarcoma	9.9e-05	0.00124	CcSEcCtD
Captopril—Dysgeusia—Doxorubicin—sarcoma	9.88e-05	0.00124	CcSEcCtD
Captopril—Malaise—Epirubicin—sarcoma	9.83e-05	0.00123	CcSEcCtD
Captopril—Nervousness—Doxorubicin—sarcoma	9.8e-05	0.00123	CcSEcCtD
Captopril—Syncope—Epirubicin—sarcoma	9.78e-05	0.00123	CcSEcCtD
Captopril—F2—Folate Metabolism—TP53—sarcoma	9.77e-05	0.00109	CbGpPWpGaD
Captopril—MMP9—Spinal Cord Injury—MYC—sarcoma	9.68e-05	0.00108	CbGpPWpGaD
Captopril—Palpitations—Epirubicin—sarcoma	9.64e-05	0.00121	CcSEcCtD
Captopril—F2—Cell surface interactions at the vascular wall—SRC—sarcoma	9.6e-05	0.00107	CbGpPWpGaD
Captopril—Loss of consciousness—Epirubicin—sarcoma	9.58e-05	0.0012	CcSEcCtD
Captopril—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—sarcoma	9.54e-05	0.00106	CbGpPWpGaD
Captopril—Cough—Epirubicin—sarcoma	9.51e-05	0.00119	CcSEcCtD
Captopril—Vision blurred—Doxorubicin—sarcoma	9.51e-05	0.00119	CcSEcCtD
Captopril—MMP9—Spinal Cord Injury—EGFR—sarcoma	9.47e-05	0.00105	CbGpPWpGaD
Captopril—Nausea—Etoposide—sarcoma	9.43e-05	0.00118	CcSEcCtD
Captopril—MMP9—Signaling by SCF-KIT—SRC—sarcoma	9.37e-05	0.00104	CbGpPWpGaD
Captopril—Ill-defined disorder—Doxorubicin—sarcoma	9.36e-05	0.00117	CcSEcCtD
Captopril—Anaemia—Doxorubicin—sarcoma	9.32e-05	0.00117	CcSEcCtD
Captopril—Myalgia—Epirubicin—sarcoma	9.28e-05	0.00116	CcSEcCtD
Captopril—Chest pain—Epirubicin—sarcoma	9.28e-05	0.00116	CcSEcCtD
Captopril—Arthralgia—Epirubicin—sarcoma	9.28e-05	0.00116	CcSEcCtD
Captopril—MMP2—Developmental Biology—KDR—sarcoma	9.26e-05	0.00103	CbGpPWpGaD
Captopril—F2—Cell surface interactions at the vascular wall—NRAS—sarcoma	9.23e-05	0.00103	CbGpPWpGaD
Captopril—Discomfort—Epirubicin—sarcoma	9.17e-05	0.00115	CcSEcCtD
Captopril—MMP9—EPH-Ephrin signaling—HRAS—sarcoma	9.12e-05	0.00102	CbGpPWpGaD
Captopril—Malaise—Doxorubicin—sarcoma	9.1e-05	0.00114	CcSEcCtD
Captopril—Dry mouth—Epirubicin—sarcoma	9.08e-05	0.00114	CcSEcCtD
Captopril—Syncope—Doxorubicin—sarcoma	9.05e-05	0.00113	CcSEcCtD
Captopril—MMP9—Signaling by SCF-KIT—NRAS—sarcoma	9.01e-05	0.001	CbGpPWpGaD
Captopril—REN—Metabolism of proteins—CTNNB1—sarcoma	9e-05	0.001	CbGpPWpGaD
Captopril—Confusional state—Epirubicin—sarcoma	8.97e-05	0.00112	CcSEcCtD
Captopril—Palpitations—Doxorubicin—sarcoma	8.92e-05	0.00112	CcSEcCtD
Captopril—Anaphylactic shock—Epirubicin—sarcoma	8.9e-05	0.00112	CcSEcCtD
Captopril—Loss of consciousness—Doxorubicin—sarcoma	8.87e-05	0.00111	CcSEcCtD
Captopril—Cough—Doxorubicin—sarcoma	8.8e-05	0.0011	CcSEcCtD
Captopril—Shock—Epirubicin—sarcoma	8.75e-05	0.0011	CcSEcCtD
Captopril—Thrombocytopenia—Epirubicin—sarcoma	8.71e-05	0.00109	CcSEcCtD
Captopril—Tachycardia—Epirubicin—sarcoma	8.68e-05	0.00109	CcSEcCtD
Captopril—CYP2D6—testis—sarcoma	8.61e-05	0.000608	CbGeAlD
Captopril—Myalgia—Doxorubicin—sarcoma	8.59e-05	0.00108	CcSEcCtD
Captopril—Arthralgia—Doxorubicin—sarcoma	8.59e-05	0.00108	CcSEcCtD
Captopril—Chest pain—Doxorubicin—sarcoma	8.59e-05	0.00108	CcSEcCtD
Captopril—ABCB1—uterus—sarcoma	8.53e-05	0.000603	CbGeAlD
Captopril—MMP9—Axon guidance—KDR—sarcoma	8.51e-05	0.000948	CbGpPWpGaD
Captopril—Discomfort—Doxorubicin—sarcoma	8.49e-05	0.00106	CcSEcCtD
Captopril—Anorexia—Epirubicin—sarcoma	8.48e-05	0.00106	CcSEcCtD
Captopril—F2—GPCR ligand binding—CXCR4—sarcoma	8.42e-05	0.000938	CbGpPWpGaD
Captopril—Dry mouth—Doxorubicin—sarcoma	8.4e-05	0.00105	CcSEcCtD
Captopril—ABCB1—Allograft Rejection—PDGFRA—sarcoma	8.39e-05	0.000935	CbGpPWpGaD
Captopril—Hypotension—Epirubicin—sarcoma	8.31e-05	0.00104	CcSEcCtD
Captopril—Confusional state—Doxorubicin—sarcoma	8.3e-05	0.00104	CcSEcCtD
Captopril—Anaphylactic shock—Doxorubicin—sarcoma	8.23e-05	0.00103	CcSEcCtD
Captopril—MMP9—Signaling by SCF-KIT—EGFR—sarcoma	8.21e-05	0.000915	CbGpPWpGaD
Captopril—MMP9—Extracellular matrix organization—MMP2—sarcoma	8.18e-05	0.000912	CbGpPWpGaD
Captopril—CYP2D6—liver—sarcoma	8.14e-05	0.000575	CbGeAlD
Captopril—MMP2—Developmental Biology—CREB1—sarcoma	8.12e-05	0.000905	CbGpPWpGaD
Captopril—Musculoskeletal discomfort—Epirubicin—sarcoma	8.11e-05	0.00102	CcSEcCtD
Captopril—Shock—Doxorubicin—sarcoma	8.1e-05	0.00102	CcSEcCtD
Captopril—Thrombocytopenia—Doxorubicin—sarcoma	8.06e-05	0.00101	CcSEcCtD
Captopril—Insomnia—Epirubicin—sarcoma	8.05e-05	0.00101	CcSEcCtD
Captopril—Tachycardia—Doxorubicin—sarcoma	8.04e-05	0.00101	CcSEcCtD
Captopril—F2—Gastrin-CREB signalling pathway via PKC and MAPK—CREB1—sarcoma	8e-05	0.000891	CbGpPWpGaD
Captopril—Paraesthesia—Epirubicin—sarcoma	7.99e-05	0.001	CcSEcCtD
Captopril—ABCB1—lymphoid tissue—sarcoma	7.95e-05	0.000562	CbGeAlD
Captopril—MMP9—Spinal Cord Injury—TP53—sarcoma	7.95e-05	0.000886	CbGpPWpGaD
Captopril—F2—Cell surface interactions at the vascular wall—KRAS—sarcoma	7.95e-05	0.000885	CbGpPWpGaD
Captopril—Dyspnoea—Epirubicin—sarcoma	7.93e-05	0.000994	CcSEcCtD
Captopril—Somnolence—Epirubicin—sarcoma	7.91e-05	0.000991	CcSEcCtD
Captopril—Anorexia—Doxorubicin—sarcoma	7.85e-05	0.000984	CcSEcCtD
Captopril—F2—Hemostasis—PLCG1—sarcoma	7.84e-05	0.000873	CbGpPWpGaD
Captopril—Dyspepsia—Epirubicin—sarcoma	7.83e-05	0.000982	CcSEcCtD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	7.81e-05	0.00087	CbGpPWpGaD
Captopril—MMP9—Signaling by SCF-KIT—KRAS—sarcoma	7.76e-05	0.000864	CbGpPWpGaD
Captopril—Decreased appetite—Epirubicin—sarcoma	7.74e-05	0.000969	CcSEcCtD
Captopril—Hypotension—Doxorubicin—sarcoma	7.69e-05	0.000964	CcSEcCtD
Captopril—ALB—Platelet activation, signaling and aggregation—VEGFC—sarcoma	7.68e-05	0.000856	CbGpPWpGaD
Captopril—Fatigue—Epirubicin—sarcoma	7.67e-05	0.000961	CcSEcCtD
Captopril—Constipation—Epirubicin—sarcoma	7.61e-05	0.000954	CcSEcCtD
Captopril—Musculoskeletal discomfort—Doxorubicin—sarcoma	7.5e-05	0.00094	CcSEcCtD
Captopril—MMP9—Axon guidance—CREB1—sarcoma	7.46e-05	0.000832	CbGpPWpGaD
Captopril—Insomnia—Doxorubicin—sarcoma	7.45e-05	0.000933	CcSEcCtD
Captopril—Paraesthesia—Doxorubicin—sarcoma	7.39e-05	0.000926	CcSEcCtD
Captopril—MMP9—Developmental Biology—FOXO1—sarcoma	7.34e-05	0.000818	CbGpPWpGaD
Captopril—Dyspnoea—Doxorubicin—sarcoma	7.34e-05	0.00092	CcSEcCtD
Captopril—MMP2—Axon guidance—SRC—sarcoma	7.34e-05	0.000818	CbGpPWpGaD
Captopril—Feeling abnormal—Epirubicin—sarcoma	7.33e-05	0.000919	CcSEcCtD
Captopril—Somnolence—Doxorubicin—sarcoma	7.32e-05	0.000917	CcSEcCtD
Captopril—Gastrointestinal pain—Epirubicin—sarcoma	7.28e-05	0.000912	CcSEcCtD
Captopril—Dyspepsia—Doxorubicin—sarcoma	7.25e-05	0.000908	CcSEcCtD
Captopril—ABCB1—bone marrow—sarcoma	7.24e-05	0.000512	CbGeAlD
Captopril—Decreased appetite—Doxorubicin—sarcoma	7.16e-05	0.000897	CcSEcCtD
Captopril—ABCB1—HIF-1-alpha transcription factor network—CREB1—sarcoma	7.15e-05	0.000797	CbGpPWpGaD
Captopril—MMP2—Axon guidance—VEGFA—sarcoma	7.15e-05	0.000796	CbGpPWpGaD
Captopril—Fatigue—Doxorubicin—sarcoma	7.1e-05	0.00089	CcSEcCtD
Captopril—MMP2—Axon guidance—NRAS—sarcoma	7.06e-05	0.000787	CbGpPWpGaD
Captopril—Constipation—Doxorubicin—sarcoma	7.04e-05	0.000882	CcSEcCtD
Captopril—Abdominal pain—Epirubicin—sarcoma	7.03e-05	0.000882	CcSEcCtD
Captopril—Body temperature increased—Epirubicin—sarcoma	7.03e-05	0.000882	CcSEcCtD
Captopril—MMP9—Axon guidance—MMP2—sarcoma	6.95e-05	0.000774	CbGpPWpGaD
Captopril—Feeling abnormal—Doxorubicin—sarcoma	6.78e-05	0.00085	CcSEcCtD
Captopril—F2—Cell surface interactions at the vascular wall—HRAS—sarcoma	6.75e-05	0.000753	CbGpPWpGaD
Captopril—Gastrointestinal pain—Doxorubicin—sarcoma	6.73e-05	0.000844	CcSEcCtD
Captopril—F2—Regulation of Actin Cytoskeleton—NRAS—sarcoma	6.66e-05	0.000742	CbGpPWpGaD
Captopril—MMP9—Signaling by SCF-KIT—HRAS—sarcoma	6.59e-05	0.000735	CbGpPWpGaD
Captopril—Body temperature increased—Doxorubicin—sarcoma	6.51e-05	0.000816	CcSEcCtD
Captopril—Abdominal pain—Doxorubicin—sarcoma	6.51e-05	0.000816	CcSEcCtD
Captopril—MMP2—Axon guidance—EGFR—sarcoma	6.43e-05	0.000717	CbGpPWpGaD
Captopril—Asthenia—Epirubicin—sarcoma	6.38e-05	0.0008	CcSEcCtD
Captopril—Pruritus—Epirubicin—sarcoma	6.3e-05	0.000789	CcSEcCtD
Captopril—ABCB1—testis—sarcoma	6.19e-05	0.000438	CbGeAlD
Captopril—Diarrhoea—Epirubicin—sarcoma	6.09e-05	0.000763	CcSEcCtD
Captopril—MMP2—Axon guidance—KRAS—sarcoma	6.08e-05	0.000677	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—KDR—sarcoma	6.07e-05	0.000677	CbGpPWpGaD
Captopril—F2—Regulation of Actin Cytoskeleton—EGFR—sarcoma	6.06e-05	0.000676	CbGpPWpGaD
Captopril—ALB—Folate Metabolism—IL2—sarcoma	6.04e-05	0.000673	CbGpPWpGaD
Captopril—Asthenia—Doxorubicin—sarcoma	5.91e-05	0.00074	CcSEcCtD
Captopril—Dizziness—Epirubicin—sarcoma	5.88e-05	0.000737	CcSEcCtD
Captopril—ABCB1—liver—sarcoma	5.85e-05	0.000414	CbGeAlD
Captopril—Pruritus—Doxorubicin—sarcoma	5.83e-05	0.00073	CcSEcCtD
Captopril—MMP2—Developmental Biology—CTNNB1—sarcoma	5.79e-05	0.000646	CbGpPWpGaD
Captopril—F2—Platelet activation, signaling and aggregation—IL2—sarcoma	5.78e-05	0.000645	CbGpPWpGaD
Captopril—F2—Regulation of Actin Cytoskeleton—KRAS—sarcoma	5.73e-05	0.000638	CbGpPWpGaD
Captopril—Vomiting—Epirubicin—sarcoma	5.66e-05	0.000709	CcSEcCtD
Captopril—Diarrhoea—Doxorubicin—sarcoma	5.63e-05	0.000706	CcSEcCtD
Captopril—Rash—Epirubicin—sarcoma	5.61e-05	0.000703	CcSEcCtD
Captopril—Dermatitis—Epirubicin—sarcoma	5.61e-05	0.000702	CcSEcCtD
Captopril—Headache—Epirubicin—sarcoma	5.57e-05	0.000699	CcSEcCtD
Captopril—Dizziness—Doxorubicin—sarcoma	5.44e-05	0.000682	CcSEcCtD
Captopril—ALB—Hemostasis—TEK—sarcoma	5.39e-05	0.000601	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—CREB1—sarcoma	5.33e-05	0.000593	CbGpPWpGaD
Captopril—Nausea—Epirubicin—sarcoma	5.29e-05	0.000662	CcSEcCtD
Captopril—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—sarcoma	5.25e-05	0.000585	CbGpPWpGaD
Captopril—ACE—Metabolism of proteins—MMP2—sarcoma	5.24e-05	0.000584	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—SRC—sarcoma	5.24e-05	0.000584	CbGpPWpGaD
Captopril—Vomiting—Doxorubicin—sarcoma	5.24e-05	0.000656	CcSEcCtD
Captopril—Rash—Doxorubicin—sarcoma	5.19e-05	0.000651	CcSEcCtD
Captopril—MMP9—Signaling Pathways—TLE1—sarcoma	5.19e-05	0.000578	CbGpPWpGaD
Captopril—Dermatitis—Doxorubicin—sarcoma	5.19e-05	0.00065	CcSEcCtD
Captopril—MMP2—Axon guidance—HRAS—sarcoma	5.17e-05	0.000576	CbGpPWpGaD
Captopril—Headache—Doxorubicin—sarcoma	5.16e-05	0.000646	CcSEcCtD
Captopril—ABCB1—HIF-1-alpha transcription factor network—JUN—sarcoma	5.14e-05	0.000573	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—VEGFA—sarcoma	5.1e-05	0.000568	CbGpPWpGaD
Captopril—F2—Platelet activation, signaling and aggregation—SRC—sarcoma	5.05e-05	0.000562	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—NRAS—sarcoma	5.04e-05	0.000561	CbGpPWpGaD
Captopril—F2—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—sarcoma	4.96e-05	0.000553	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—MMP2—sarcoma	4.96e-05	0.000552	CbGpPWpGaD
Captopril—ALB—Hemostasis—ANGPT2—sarcoma	4.93e-05	0.00055	CbGpPWpGaD
Captopril—F2—Platelet activation, signaling and aggregation—VEGFA—sarcoma	4.92e-05	0.000548	CbGpPWpGaD
Captopril—Nausea—Doxorubicin—sarcoma	4.89e-05	0.000613	CcSEcCtD
Captopril—MMP9—Axon guidance—SRC—sarcoma	4.81e-05	0.000536	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—CXCR4—sarcoma	4.76e-05	0.00053	CbGpPWpGaD
Captopril—MMP9—Axon guidance—VEGFA—sarcoma	4.69e-05	0.000522	CbGpPWpGaD
Captopril—MMP9—Axon guidance—NRAS—sarcoma	4.63e-05	0.000516	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—EGFR—sarcoma	4.59e-05	0.000511	CbGpPWpGaD
Captopril—ABCB1—Allograft Rejection—IL2—sarcoma	4.58e-05	0.00051	CbGpPWpGaD
Captopril—F2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—sarcoma	4.52e-05	0.000504	CbGpPWpGaD
Captopril—ABCB1—HIF-1-alpha transcription factor network—VEGFA—sarcoma	4.49e-05	0.000501	CbGpPWpGaD
Captopril—ABCB1—lymph node—sarcoma	4.49e-05	0.000317	CbGeAlD
Captopril—MMP2—Metabolism of proteins—CTNNB1—sarcoma	4.47e-05	0.000498	CbGpPWpGaD
Captopril—ALB—Platelet degranulation—VEGFA—sarcoma	4.4e-05	0.00049	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—VEGFC—sarcoma	4.38e-05	0.000488	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—KRAS—sarcoma	4.34e-05	0.000483	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—CXCR4—sarcoma	4.32e-05	0.000482	CbGpPWpGaD
Captopril—F2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—sarcoma	4.27e-05	0.000476	CbGpPWpGaD
Captopril—MMP9—Axon guidance—EGFR—sarcoma	4.22e-05	0.00047	CbGpPWpGaD
Captopril—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—sarcoma	4.19e-05	0.000467	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	4.14e-05	0.000462	CbGpPWpGaD
Captopril—ACE—Metabolism of proteins—CTNNB1—sarcoma	4.02e-05	0.000448	CbGpPWpGaD
Captopril—F2—Signaling Pathways—TLE1—sarcoma	4.01e-05	0.000447	CbGpPWpGaD
Captopril—MMP9—Axon guidance—KRAS—sarcoma	3.99e-05	0.000444	CbGpPWpGaD
Captopril—ALB—Hemostasis—VEGFC—sarcoma	3.96e-05	0.000441	CbGpPWpGaD
Captopril—ABCB1—Allograft Rejection—VEGFA—sarcoma	3.89e-05	0.000434	CbGpPWpGaD
Captopril—ALB—Folate Metabolism—TP53—sarcoma	3.88e-05	0.000432	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—CTNNB1—sarcoma	3.8e-05	0.000423	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—HRAS—sarcoma	3.69e-05	0.000411	CbGpPWpGaD
Captopril—F2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—sarcoma	3.63e-05	0.000405	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—FLT1—sarcoma	3.5e-05	0.00039	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—PLCG1—sarcoma	3.44e-05	0.000383	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—SRC—sarcoma	3.44e-05	0.000383	CbGpPWpGaD
Captopril—MMP9—Axon guidance—HRAS—sarcoma	3.39e-05	0.000378	CbGpPWpGaD
Captopril—F2—Signaling Pathways—VEGFC—sarcoma	3.38e-05	0.000377	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—VEGFA—sarcoma	3.35e-05	0.000373	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—CXCR4—sarcoma	3.31e-05	0.000368	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—NRAS—sarcoma	3.3e-05	0.000368	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—ATF1—sarcoma	3.27e-05	0.000364	CbGpPWpGaD
Captopril—ALB—Hemostasis—PLCG1—sarcoma	3.11e-05	0.000347	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	3.06e-05	0.000341	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—EGFR—sarcoma	3.01e-05	0.000336	CbGpPWpGaD
Captopril—F2—Hemostasis—IL2—sarcoma	2.98e-05	0.000332	CbGpPWpGaD
Captopril—F2—Metabolism of proteins—MMP2—sarcoma	2.95e-05	0.000329	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—KRAS—sarcoma	2.84e-05	0.000317	CbGpPWpGaD
Captopril—F2—Signaling Pathways—FLT1—sarcoma	2.7e-05	0.000301	CbGpPWpGaD
Captopril—F2—Signaling Pathways—PLCG1—sarcoma	2.66e-05	0.000296	CbGpPWpGaD
Captopril—F2—Hemostasis—SRC—sarcoma	2.6e-05	0.00029	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—IGF1R—sarcoma	2.57e-05	0.000286	CbGpPWpGaD
Captopril—F2—Signaling Pathways—CXCR4—sarcoma	2.55e-05	0.000284	CbGpPWpGaD
Captopril—F2—Hemostasis—VEGFA—sarcoma	2.53e-05	0.000282	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	2.53e-05	0.000282	CbGpPWpGaD
Captopril—F2—Signaling Pathways—ATF1—sarcoma	2.52e-05	0.000281	CbGpPWpGaD
Captopril—F2—Hemostasis—NRAS—sarcoma	2.5e-05	0.000279	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—FOXO1—sarcoma	2.44e-05	0.000272	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—PDGFRB—sarcoma	2.44e-05	0.000272	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—HRAS—sarcoma	2.42e-05	0.000269	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—PDGFRA—sarcoma	2.4e-05	0.000267	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—CREB1—sarcoma	2.31e-05	0.000258	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—IL2—sarcoma	2.3e-05	0.000256	CbGpPWpGaD
Captopril—F2—Metabolism of proteins—CTNNB1—sarcoma	2.26e-05	0.000252	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	2.2e-05	0.000246	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	2.2e-05	0.000245	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	2.18e-05	0.000243	CbGpPWpGaD
Captopril—F2—Hemostasis—KRAS—sarcoma	2.15e-05	0.00024	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—KDR—sarcoma	2.02e-05	0.000225	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—SRC—sarcoma	2e-05	0.000223	CbGpPWpGaD
Captopril—F2—Signaling Pathways—IGF1R—sarcoma	1.98e-05	0.000221	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	1.97e-05	0.00022	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—VEGFA—sarcoma	1.95e-05	0.000217	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	1.92e-05	0.000214	CbGpPWpGaD
Captopril—F2—Hemostasis—TP53—sarcoma	1.91e-05	0.000213	CbGpPWpGaD
Captopril—F2—Signaling Pathways—FOXO1—sarcoma	1.89e-05	0.00021	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—IL2—sarcoma	1.88e-05	0.00021	CbGpPWpGaD
Captopril—F2—Signaling Pathways—PDGFRB—sarcoma	1.88e-05	0.00021	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—KIT—sarcoma	1.86e-05	0.000207	CbGpPWpGaD
Captopril—F2—Signaling Pathways—PDGFRA—sarcoma	1.85e-05	0.000206	CbGpPWpGaD
Captopril—F2—Hemostasis—HRAS—sarcoma	1.83e-05	0.000204	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—CREB1—sarcoma	1.77e-05	0.000197	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	1.77e-05	0.000197	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	1.73e-05	0.000193	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—IL2—sarcoma	1.71e-05	0.000191	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	1.63e-05	0.000182	CbGpPWpGaD
Captopril—F2—Signaling Pathways—KDR—sarcoma	1.56e-05	0.000174	CbGpPWpGaD
Captopril—ALB—Metabolism—ENO2—sarcoma	1.49e-05	0.000166	CbGpPWpGaD
Captopril—ALB—Metabolism—HBA1—sarcoma	1.48e-05	0.000165	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—MDM2—sarcoma	1.47e-05	0.000163	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	1.45e-05	0.000162	CbGpPWpGaD
Captopril—F2—Signaling Pathways—KIT—sarcoma	1.44e-05	0.00016	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—NRAS—sarcoma	1.44e-05	0.00016	CbGpPWpGaD
Captopril—F2—Signaling Pathways—CREB1—sarcoma	1.37e-05	0.000152	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—IL2—sarcoma	1.31e-05	0.000146	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—EGFR—sarcoma	1.31e-05	0.000146	CbGpPWpGaD
Captopril—ABCB1—Metabolism—ENO2—sarcoma	1.3e-05	0.000145	CbGpPWpGaD
Captopril—ABCB1—Metabolism—HBA1—sarcoma	1.29e-05	0.000144	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—CCND1—sarcoma	1.28e-05	0.000142	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—JUN—sarcoma	1.27e-05	0.000142	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—CTNNB1—sarcoma	1.26e-05	0.000141	CbGpPWpGaD
Captopril—ALB—Metabolism—PLCG1—sarcoma	1.26e-05	0.00014	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—KRAS—sarcoma	1.24e-05	0.000138	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—ENO2—sarcoma	1.23e-05	0.000137	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—HBA1—sarcoma	1.22e-05	0.000136	CbGpPWpGaD
Captopril—ALB—Hemostasis—IL2—sarcoma	1.18e-05	0.000132	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—SRC—sarcoma	1.14e-05	0.000127	CbGpPWpGaD
Captopril—F2—Signaling Pathways—MDM2—sarcoma	1.13e-05	0.000126	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—VEGFA—sarcoma	1.11e-05	0.000124	CbGpPWpGaD
Captopril—ABCB1—Metabolism—PLCG1—sarcoma	1.1e-05	0.000123	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—NRAS—sarcoma	1.1e-05	0.000122	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—HRAS—sarcoma	1.05e-05	0.000117	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—PLCG1—sarcoma	1.04e-05	0.000116	CbGpPWpGaD
Captopril—ALB—Hemostasis—SRC—sarcoma	1.03e-05	0.000115	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—MYC—sarcoma	1.02e-05	0.000114	CbGpPWpGaD
Captopril—F2—Signaling Pathways—IL2—sarcoma	1.01e-05	0.000113	CbGpPWpGaD
Captopril—ALB—Hemostasis—VEGFA—sarcoma	1.01e-05	0.000112	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—EGFR—sarcoma	1e-05	0.000112	CbGpPWpGaD
Captopril—ALB—Hemostasis—NRAS—sarcoma	9.93e-06	0.000111	CbGpPWpGaD
Captopril—F2—Signaling Pathways—CCND1—sarcoma	9.85e-06	0.00011	CbGpPWpGaD
Captopril—F2—Signaling Pathways—JUN—sarcoma	9.83e-06	0.00011	CbGpPWpGaD
Captopril—F2—Signaling Pathways—CTNNB1—sarcoma	9.76e-06	0.000109	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—KRAS—sarcoma	9.46e-06	0.000105	CbGpPWpGaD
Captopril—F2—Signaling Pathways—SRC—sarcoma	8.82e-06	9.83e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—VEGFA—sarcoma	8.59e-06	9.57e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—KRAS—sarcoma	8.55e-06	9.53e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—NRAS—sarcoma	8.49e-06	9.46e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—TP53—sarcoma	8.41e-06	9.37e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—HRAS—sarcoma	8.04e-06	8.96e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—MYC—sarcoma	7.9e-06	8.81e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—EGFR—sarcoma	7.73e-06	8.62e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—TP53—sarcoma	7.6e-06	8.47e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—KRAS—sarcoma	7.3e-06	8.14e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—HRAS—sarcoma	7.27e-06	8.1e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—TP53—sarcoma	6.49e-06	7.23e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—HRAS—sarcoma	6.21e-06	6.92e-05	CbGpPWpGaD
